156 related articles for article (PubMed ID: 7825805)
21. Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol.
Lissoni P; Pittalis S; Rovelli F; Zecchini S; Casati M; Tremolada M; Pelizzoni F
J Biol Regul Homeost Agents; 1996; 10(1):27-30. PubMed ID: 9049779
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
Lissoni P; Barni S; Tancini G; Ardizzoia A; Rovelli F; Cazzaniga M; Brivio F; Piperno A; Aldeghi R; Fossati D
Br J Cancer; 1993 Jun; 67(6):1404-7. PubMed ID: 8512825
[TBL] [Abstract][Full Text] [Related]
23. In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer.
Lissoni P; Barni S; Tisi E; Rovelli F; Pittalis S; Rescaldani R; Vigoré L; Biondi A; Ardizzoia A; Tancini G
Eur J Cancer; 1993; 29A(8):1127-32. PubMed ID: 8390845
[TBL] [Abstract][Full Text] [Related]
24. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms.
Lissoni P; Giani L; Zerbini S; Trabattoni P; Rovelli F
Nat Immun; 1998; 16(1):27-33. PubMed ID: 9789122
[TBL] [Abstract][Full Text] [Related]
25. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
Lissoni P; Barni S; Tancini G; Mainini E; Piglia F; Maestroni GJ; Lewinski A
Oncology; 1995; 52(2):163-6. PubMed ID: 7854778
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
Lissoni P; Rovelli F; Giani L; Fumagalli L; Mandalà M
Nat Immun; 1998; 16(5-6):178-84. PubMed ID: 11061586
[TBL] [Abstract][Full Text] [Related]
27. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study.
Lissoni P; Malugani F; Brivio F; Piazza A; Vintimilla C; Giani L; Tancini G
Neuro Endocrinol Lett; 2003; 24(3-4):259-62. PubMed ID: 14523367
[TBL] [Abstract][Full Text] [Related]
28. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent.
Lissoni P
Pathol Biol (Paris); 2007; 55(3-4):198-200. PubMed ID: 17451889
[TBL] [Abstract][Full Text] [Related]
29. Modulation of cytokine production from TH2-lymphocytes and monocytes by the pineal neurohormone melatonin.
Lissoni P; Pittalis S; Rovelli F; Roselli M; Ardizzoia A
Oncol Rep; 1996 May; 3(3):541-3. PubMed ID: 21594408
[TBL] [Abstract][Full Text] [Related]
30. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
Lissoni P; Tisi E; Barni S; Ardizzoia A; Rovelli F; Rescaldani R; Ballabio D; Benenti C; Angeli M; Tancini G
Br J Cancer; 1992 Jul; 66(1):155-8. PubMed ID: 1322155
[TBL] [Abstract][Full Text] [Related]
31. Cancer as the main aging factor for humans: the fundamental role of 5-methoxy-tryptamine in reversal of cancer-induced aging processes in metabolic and immune reactions by non-melatonin pineal hormones.
Lissoni P; Messina G; Rovelli F
Curr Aging Sci; 2012 Dec; 5(3):231-5. PubMed ID: 23451999
[TBL] [Abstract][Full Text] [Related]
32. MLT and the immune-hematopoietic system.
Maestroni GJ
Adv Exp Med Biol; 1999; 460():395-405. PubMed ID: 10810540
[TBL] [Abstract][Full Text] [Related]
33. Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study.
Lissoni P; Vigorè L; Rescaldani R; Rovelli F; Brivio F; Giani L; Barni S; Tancini G; Ardizzoia A; Viganò MG
J Biol Regul Homeost Agents; 1995; 9(4):155-8. PubMed ID: 8844341
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer.
Lissoni P; Pittalis S; Rovelli F; Vigorè L; Roselli MG; Brivio F
J Biol Regul Homeost Agents; 1995; 9(2):63-6. PubMed ID: 9127635
[TBL] [Abstract][Full Text] [Related]
35. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
[TBL] [Abstract][Full Text] [Related]
36. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone.
Lissoni P; Rovelli F; Frassineti A; Fumagalli L; Malysheva O; Conti A; Maestroni G
Neuro Endocrinol Lett; 2000; 21(4):319-323. PubMed ID: 11455367
[TBL] [Abstract][Full Text] [Related]
37. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
Lissoni P; Barni S; Ardizzoia A; Olivini G; Brivio F; Tisi E; Tancini G; Characiejus D; Kothari L
J Biol Regul Homeost Agents; 1993; 7(4):121-5. PubMed ID: 8023699
[TBL] [Abstract][Full Text] [Related]
38. A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia.
Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Ardizzoia A; Tancini G
Oncology; 1995; 52(5):360-2. PubMed ID: 7637951
[TBL] [Abstract][Full Text] [Related]
39. Melatonin as biological response modifier in cancer patients.
Neri B; de Leonardis V; Gemelli MT; di Loro F; Mottola A; Ponchietti R; Raugei A; Cini G
Anticancer Res; 1998; 18(2B):1329-32. PubMed ID: 9615811
[TBL] [Abstract][Full Text] [Related]
40. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
Lissoni P; Brivio F; Barni S; Tancini G; Cattaneo G; Archili C; Conti A; Maestroni GJ
Anticancer Res; 1990; 10(6):1759-61. PubMed ID: 2285255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
